Cytarabine
DNA synthesis and transcription disruptor / A nucleoside analog that interferes with DNA synthesis and transcription, particularly in tumor cells.1,2 It Cellular enzymes convert it to its nucleotide form, Ara-CTP, which disrupts DNA and RNA synthesis when polymerases attempt to incorporate it.3,4 For the same reasons, it is also employed as an antiviral.5 It inhibits proliferation of a variety of leukemic cell lines (IC50s 16-72 nM), but is used primarily against acute myeloid leukemia (AML).6,7
Biochemicals & reagents
147-94-4
Arabinocytidine; Cytosine β-D-Arabinofuranoside; U-19920A; Ara-C
1) Derissen & Beijnen (2020), Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action; Clin. Pharmacokinet., 59 1521 2) Z Li et al. (2017), Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells; Molecules, 22 E499 3) Zhang & Kiechle (2004), Cytosine Arabinoside Substitution Decreases Transcription Factor-DNA Binding Element Complex Formation; Arch. Pathol. Lab. Med., 128 1364 4) Renis (1973), Antiviral Activity of Cytarabine in Herpesvirus-Infected Rats; Antimicrob. Agents Chemother., 4 439 5) Qin et al. (2007), Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines; Clin. Cancer Res., 13 4225 6) Walter et al. (2020), Optimal Dosing of Cytarabine in Induction and Post-Remission Therapy of Acute Myeloid Leukemia; Leukemia, Dec 16 Online ahead of print
-20°C
TARGET: DNA; RNA -- PATHWAY: DNA damage; Cytotoxicity; Proliferation; Transcription -- RESEARCH AREA: Cell death -- DISEASE AREA: Cancer; Infectious disease